In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in

Chinyere Nwabugwu1, Kavya Rakhra, Dean Felsher

  • 1Department of Electrical Engineering, Stanford University School of Medicine, Stanford, CA 94305, USA.

Insights

Targeting oncogenes offers a therapeutic window, but tumor relapse is common. This study develops a mathematical model to understand tumor responses to oncogene inactivation, crucial for preventing relapse.

Area of Science:

  • Oncology
  • Mathematical Biology
  • Immunology

Background:

  • Targeted cancer therapies exploit oncogene overexpression but often lead to relapse.
  • Tumor regression involves complex cellular responses and immune-mediated mechanisms crucial for preventing relapse.

Purpose of the Study:

  • To develop an integrative mathematical model predicting tumor response to oncogene inactivation.
  • To understand the multifaceted cellular responses and immune interactions vital for sustained tumor regression.

Main Methods:

  • Developed an integrative mathematical model incorporating heterogeneous tumor cell states and stochastic transitions.
  • Utilized delay differential equations to accurately model tumor growth kinetics.
  • Applied the model to study oncogene addiction in MYC-induced lymphoma, osteosarcoma, and hepatocellular carcinoma.

Main Results:

  • The model accurately predicts the time course of events and tumor burden following oncogene inactivation.
  • Heterogeneous tumor cell states and stochastic transitions are essential for recapitulating experimental results and modeling resistance.
  • The model successfully captures tumor growth kinetics observed in experimental settings.

Conclusions:

  • Understanding tumor cell heterogeneity and dynamic state transitions is key to overcoming resistance to targeted therapies.
  • Mathematical modeling provides critical insights into the complex interplay of cellular responses and immune mechanisms in tumor regression.
  • This approach aids in developing strategies to prevent relapse in cancers driven by oncogene addiction.